This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Independent Multicenter Trial Demonstrates Utility Of BGM Galectin-3(R) Test For Accurately Classifying Risk Of Unplanned Hospital Readmissions And Adverse Outcomes In Patients With Heart Failure

Stocks in this article: BGMD

WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 ® Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]

The physicians who led the study reported that the inclusion of galectin-3 testing into the observational trial's hospital discharge risk planning model significantly improved the accuracy with which patient risk upon discharge could be assigned. Galectin-3 testing correctly identified markedly elevated risk among nearly one-quarter (24.3%) of all patients who, without galectin-3 testing, were otherwise inappropriately placed into the lowest risk category at the time of their initial hospital discharge but who went on to be unexpectedly readmitted to hospital or suffer a fatal event (P-value < 0.001 for the net reclassification improvement statistic).

"This independent clinical research study, conducted with a real world cohort of heart failure patients, further demonstrates the utility of galectin-3 as a sentinel marker for adverse outcomes in heart failure patients after hospital discharge," said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc.

In the trial, the results of which were reported in the November 5, 2013 issue of the International Journal of Cardiology, the authors, from four hospitals and university clinics across Spain, further reported that heart failure patients with elevated galectin-3 levels had rates of hospital readmission and fatal events that were 84% higher than those of patients with lower galectin-3 levels (P-value < 0.0001). The higher risk conferred by elevated galectin-3 levels was independent of, and additive to, other clinical risk variables considered for these patients, including impaired kidney function, age, diabetes, anemia, heart failure disease severity, and blood levels of the natriuretic peptide NT-proBNP, sodium and urea (P-value = 0.015 for galectin-3 upon full statistical adjustment). Subjects enrolled in the trial were acute heart failure patients, with commonly associated comorbidities and medication usage patterns, who were consecutively admitted to participating hospital centers. This real world cohort of patients spanned both mildly depressed and preserved left ventricular ejection fraction as well as a broad range of disease severity.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs